ALL KEYWORDS
Head and Neck Cancer Genomics
Related Specialists
Showing 3 of 13
Related Fact Sheets
Related Clinical Trials
Showing 2 of 8
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Head & Neck Cancers
- Gender:All Genders
- Age:18 years and older
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)
- Head & Neck Cancers
- Gender:All Genders
- Age:18 years and older
Related Departments
Showing 3 of 35